Der foretages fortsat tests og clinical trials af NGAL som biomarkør for akut nyreskade. Alle disse test og trials har indtil nu været indiskutabelt positive, og valideret NGAL som fremtidens stof på markedet - her den seneste offentliggørelse:
http://www.reuters.com/article/healthNews/idUSTRE5154GR20090206
I nedenstående test - en af mange nuværende - tester Biosite/Inverness deres point-of-care Triage kit på en skadestue, hvilket efterhånden bør få FDA til at finde godkendelses-stemplet frem - testen gennemført i juni:
http://clinicaltrials.gov/ct2/show/NCT00845741
( her en lignende fra Abbott: http://clinicaltrials.gov/ct2/show/NCT00786708?term=ngal+abbott&rank=1 )
("Demonstration of similarly robust sensitivity and specificity in a broad Emergency Room population would strengthen the conception of NGAL as a marker of early or advancing kidney dysfunction. Most importantly, if NGAL can distinguish between types of renal disease at presentation in the ER, it might have important implications regarding ER management of these common presentations. For example, it could reduce diagnostic ambiguity and lag time from hours or days to seconds.")
Her en mere grundlæggende test, hvor konklusionen forefindes i denne måned:
http://clinicaltrials.gov/ct2/show/NCT00445809?term=NGAL&rank=6
(Mon Biosite venter på svar fra denne, inden de vil skrive med BioPorto?)
Også Abbotts Architect assay venter på FDA-godkendelse for brug i USA, men som hos Biosite ventes produktet lanceret i Europa i en meget nær fremtid. Hvad Roche, Siemens, Beckman-Coulter etc. har af planer er uvist, men sikkert er det, at der skal skrives licensaftale med BioPorto, hvis, i første omgang Abbott og Biosite, vil sælge deres kits, og ikke blot have dem liggende.
"Bioporto har vurderet, at behovet på verdensmarkedet er omkring 175 mio. test på årsbasis. Det svarer til, at alle patienter på intensivafdelinger testes to gange dagligt. En gennemsnitstest koster 90-110 kr., svarende til et markedspotentiale på 16-19 mia. kr."
Jeg har naturligvis selv aktier i foretagende, og er glad for, mine penge er placeret dér - særligt nu hvor Krise II er i fuld sving.
Mvh
http://www.reuters.com/article/healthNews/idUSTRE5154GR20090206
I nedenstående test - en af mange nuværende - tester Biosite/Inverness deres point-of-care Triage kit på en skadestue, hvilket efterhånden bør få FDA til at finde godkendelses-stemplet frem - testen gennemført i juni:
http://clinicaltrials.gov/ct2/show/NCT00845741
( her en lignende fra Abbott: http://clinicaltrials.gov/ct2/show/NCT00786708?term=ngal+abbott&rank=1 )
("Demonstration of similarly robust sensitivity and specificity in a broad Emergency Room population would strengthen the conception of NGAL as a marker of early or advancing kidney dysfunction. Most importantly, if NGAL can distinguish between types of renal disease at presentation in the ER, it might have important implications regarding ER management of these common presentations. For example, it could reduce diagnostic ambiguity and lag time from hours or days to seconds.")
Her en mere grundlæggende test, hvor konklusionen forefindes i denne måned:
http://clinicaltrials.gov/ct2/show/NCT00445809?term=NGAL&rank=6
(Mon Biosite venter på svar fra denne, inden de vil skrive med BioPorto?)
Også Abbotts Architect assay venter på FDA-godkendelse for brug i USA, men som hos Biosite ventes produktet lanceret i Europa i en meget nær fremtid. Hvad Roche, Siemens, Beckman-Coulter etc. har af planer er uvist, men sikkert er det, at der skal skrives licensaftale med BioPorto, hvis, i første omgang Abbott og Biosite, vil sælge deres kits, og ikke blot have dem liggende.
"Bioporto har vurderet, at behovet på verdensmarkedet er omkring 175 mio. test på årsbasis. Det svarer til, at alle patienter på intensivafdelinger testes to gange dagligt. En gennemsnitstest koster 90-110 kr., svarende til et markedspotentiale på 16-19 mia. kr."
Jeg har naturligvis selv aktier i foretagende, og er glad for, mine penge er placeret dér - særligt nu hvor Krise II er i fuld sving.
Mvh
2/3 2009 15:45 faurschou 0
3515 Det er heller ikke produktet, der bekymrer mig. Det er mere virksomhedens evner til at kommunikere til aktionærerne og forhandle med Big Pharma. Jo mere man lover en aftale jo mere forhandler man sig selv op i et hjørne. Der skal forhandles og kommunikeres benhårdt, hvilket jeg f.eks. syntes svigtede da CCH fik godkendt sit patent, og BioP's første udmelding åbnede for at CCH's patent kunne få stor betydning.
Jeg håber BioP får forhandlet en god aftale i hus, det ville være godt for mit aktieår.
Jeg håber BioP får forhandlet en god aftale i hus, det ville være godt for mit aktieår.
2/3 2009 16:50 ndrs 03519 Fuldstændig enig. Hvad end der måtte være af forklaringer og undskyldninger, er ledelsens evindelige brudte løfter efterhånden grænsende til det pinagtigte - ihvertfald er det indiskutabelt ikke godkendt!
Selv på trods af denne amatørforestilling, er papiret dog, for mig, interessant. Her var endnu en omgang clinical trials:
http://clinicaltrial.gov/ct2/show?term=NGAL&rank=4
Derudover bliver det meget interessant at se, hvad BioPorto selv har genereret af indkomst. Firmaet sælger selv bl.a. NGAL Rapid ELISA Kits, hvilke der jo burde være en god interesse for, til diagnostisk brug i EU, Canada og Indien (og til forskning i resten af verden) samt flere andre interessante sager. Ligeledes ser distributør-netværket efterhånden særdeles interessant ud.
Kursen virker for mig utrolig lav, og er ihvertfald ikke steget efter det f.eks. blev offentliggjort, at BioPorto "besejrede" CHH i EPO - besynderligt, men det er naturligvis gået værre for de fleste andre aktier, og det kan ikke undre, hvis mange aktionærer sætter spørgsmålstegn ved ledelsens troværdighed. Seneste udmeldte deadline for licensaftaler er Q1 2009 (altså inden denne måneds udgang) og man kan vel efterhånden kun håbe.
Jeg er ikke i tvivl om, at det blot er et spørgsmål om tid, inden BioPorto får en aftale i stand, men indtil da vil kursen desværre lide. BP har stadig fint med penge i kassen, og en tidligere tilbudt aftale er blevet afvist, men nu vil vi gerne snart have nogle gode nyheder om FDA, Biosite, Abbott og licensrettigheder!
Mvh
Selv på trods af denne amatørforestilling, er papiret dog, for mig, interessant. Her var endnu en omgang clinical trials:
http://clinicaltrial.gov/ct2/show?term=NGAL&rank=4
Derudover bliver det meget interessant at se, hvad BioPorto selv har genereret af indkomst. Firmaet sælger selv bl.a. NGAL Rapid ELISA Kits, hvilke der jo burde være en god interesse for, til diagnostisk brug i EU, Canada og Indien (og til forskning i resten af verden) samt flere andre interessante sager. Ligeledes ser distributør-netværket efterhånden særdeles interessant ud.
Kursen virker for mig utrolig lav, og er ihvertfald ikke steget efter det f.eks. blev offentliggjort, at BioPorto "besejrede" CHH i EPO - besynderligt, men det er naturligvis gået værre for de fleste andre aktier, og det kan ikke undre, hvis mange aktionærer sætter spørgsmålstegn ved ledelsens troværdighed. Seneste udmeldte deadline for licensaftaler er Q1 2009 (altså inden denne måneds udgang) og man kan vel efterhånden kun håbe.
Jeg er ikke i tvivl om, at det blot er et spørgsmål om tid, inden BioPorto får en aftale i stand, men indtil da vil kursen desværre lide. BP har stadig fint med penge i kassen, og en tidligere tilbudt aftale er blevet afvist, men nu vil vi gerne snart have nogle gode nyheder om FDA, Biosite, Abbott og licensrettigheder!
Mvh
2/3 2009 16:53 ndrs 03520 PS
Der var lige en udflugt for foretagendet:
http://bioporto.com/news/bioporto_diagnostics_at_toxexpo_baltimore_march_16_18
Der var lige en udflugt for foretagendet:
http://bioporto.com/news/bioporto_diagnostics_at_toxexpo_baltimore_march_16_18
3/3 2009 09:54 Sonku 03533 Ja, alle er vist enige om at BioP ikke ligefrem er mest kendt for at indfri deres løfter.
Guderne forbyde de ikke denne gang kommer med en aftale i Q1, men jeg kunne nu godt tænke mig at høre hvad i mener der vil ske, hvis den " smutter " endnu engang........Hvad med kursen, er der dømt blodbad, eller er vi stadig nok trofaste til den ikke ryger helt i hullet ??
Guderne forbyde de ikke denne gang kommer med en aftale i Q1, men jeg kunne nu godt tænke mig at høre hvad i mener der vil ske, hvis den " smutter " endnu engang........Hvad med kursen, er der dømt blodbad, eller er vi stadig nok trofaste til den ikke ryger helt i hullet ??
3/3 2009 09:52 stengård 03532 rigtig god opsummering. Jeg føler mig overbevist om at det IKKE er fordi selskabet ikke vil informere om forløbet som sådan - men fordi det vil skade forhandlingerne..
Som en god ven sagde - "jeg tror sgu'tte at Abbott sender en halv hær over til Grusbakken flere gange, uden at være interesserede - det der sikkert pisser dem af - er at hun skal have så mange penge for noget som de mener de skulle have haft rettighederne til via CCH..."
men når det er sagt - så tror jeg også at der ville lette på en del aktionær-ansigtsudtryk med en aftale... også mit :)
Som en god ven sagde - "jeg tror sgu'tte at Abbott sender en halv hær over til Grusbakken flere gange, uden at være interesserede - det der sikkert pisser dem af - er at hun skal have så mange penge for noget som de mener de skulle have haft rettighederne til via CCH..."
men når det er sagt - så tror jeg også at der ville lette på en del aktionær-ansigtsudtryk med en aftale... også mit :)
3/3 2009 10:12 Kim 03534 Tjah, nu ser jeg at jeg fik lov til at åbne dagens bal med endnu et "vildt" indkøb i BioPorto, hele 100 stk til 4,5.......
Håber sgu du/I får ret Stengård, det kunne jo være "sjovt" hvis ATH på 13.30 kunne brydes :o)
Mvh Kim
Håber sgu du/I får ret Stengård, det kunne jo være "sjovt" hvis ATH på 13.30 kunne brydes :o)
Mvh Kim
3/3 2009 20:02 CareTaker 03551 Mener nu godt nok at det hed over 14 intraday, som var ATH. Men ja det ville være dejligt......Og mon ikke vi får en ny ATH "når" første aftale indgåes.
"når" er sakset fra sidste nyhedsbrev....
"når" er sakset fra sidste nyhedsbrev....
9/3 2009 07:42 Kim 03895 Vil lige fortælle at der i DR's Dokumentaren på DR 1, onsdag d. 11 marts kl 20 kommer historien omkring Omniscan-skandalen. Ved godt at BioPorto og Omniscan ikke rigtigt hænger sammen, men da det har været ret meget omtalt i forbindelse med vores debatter i BioPorto, så vil jeg bare lige gøre opmærksom på udsendelsen.
mvh Kim
mvh Kim
9/3 2009 15:25 Kim 03960 Faldt lige over en kongres oversigt for 2009 som Bioporto deltage i dette år.
http://www.antibodyshop.dk/content/download/885/11471/version/27/file/Congress+overview+2009.pdf
synes godt nok ikke jeg kan finde det via deres hjemmeside.
Men må da sige der bruges en del på at gøre sig synlige.
http://www.antibodyshop.dk/content/download/885/11471/version/27/file/Congress+overview+2009.pdf
synes godt nok ikke jeg kan finde det via deres hjemmeside.
Men må da sige der bruges en del på at gøre sig synlige.
9/3 2009 15:47 DrueAgurken 03963 Jo den findes, man skal bare lige lede lidt.
Jeg faldt til gengæld over EPOLINE og noget som jeg ikke helt kan vurdere selv, så vil høre om der er nogen med et forkromet overblik.
Som jeg forstår det, så kan man nu udlede at:
Deres patentansøgning om at anvende NGAL til diagnose af nyreskader er godkendt og udstedes 11/03-2009. Metoder og agregater til at fastslå sværheden af nyreskader udstedes 18/03-2009...
MEN at testen til at vurdere om der er skade eller ej, har dumpet testen, og er blevet anset for ikke patenterbart... (1-14)
Er min formodning korrekt, og hvis ja, så må det da få en negativ betydning, da Bioporto så ikke vil tjene på "har du, har du ikke" test.
Jeg faldt til gengæld over EPOLINE og noget som jeg ikke helt kan vurdere selv, så vil høre om der er nogen med et forkromet overblik.
Som jeg forstår det, så kan man nu udlede at:
Deres patentansøgning om at anvende NGAL til diagnose af nyreskader er godkendt og udstedes 11/03-2009. Metoder og agregater til at fastslå sværheden af nyreskader udstedes 18/03-2009...
MEN at testen til at vurdere om der er skade eller ej, har dumpet testen, og er blevet anset for ikke patenterbart... (1-14)
Er min formodning korrekt, og hvis ja, så må det da få en negativ betydning, da Bioporto så ikke vil tjene på "har du, har du ikke" test.
9/3 2009 16:14 DrueAgurken 03968 http://www.epoline.org/portal/public/!ut/p/kcxml/04_Sj9SPykssy0xPLMnMz0vM0Y_QjzKLN4i3dAfJgFjGpvqRqCKOcAFfj_zcVKBwpDmQ726kH6LvrR-gX5AbGlFunK4IAEFiq1o!/delta/base64xml/L0lDVE83b0pKN3VhQ1NZS0NsRUtDbEVBIS9vUG9nQUVJUWhDRU1ZaENHSVFJU0ZHVVp6Q0FJQlFVaFM0SSEvNEIxaWNvblFWd0d4T1VUb0s3OVlRN0RtRzRSMkhLTnhpQSEhLzdfMF9HMi85MjQ1ODAvb3JnZXBvbGluZXBvcnRhbGZyYW1ld29ya3BvcnRsZXRiYXNlU3RhdGVQb3J0bGV0QmFzZUFjdGlvbi9vcm
Tryk på Register Plus oppe i hjørnet.. søg på inventor: Uttenthal, og så er det nummer 3.
Tryk på Register Plus oppe i hjørnet.. søg på inventor: Uttenthal, og så er det nummer 3.
9/3 2009 16:32 stengård 03972 hmmm .... jeg tror jeg skal bruge lidt tid til at gnave mig igennem det... har du eventuelt spurgt hos BioP ?
9/3 2009 16:44 DrueAgurken 03973 Nej, for de leget jo stilleleg atm, så jeg regner ikke med svar.
Men altså, det kan også være at jeg tager fejl, for jeg ser nu at side 4 siger at claim 1-14 ikke vil blive vurderet... (selvom der kun er claim 1-14). Så det er sikkert noget formalia pjat.
Nå, så er vi tilbage ved at det er positivt at de nu får trykt to af deres patenter på fint papir og i laminering...
Men altså, det kan også være at jeg tager fejl, for jeg ser nu at side 4 siger at claim 1-14 ikke vil blive vurderet... (selvom der kun er claim 1-14). Så det er sikkert noget formalia pjat.
Nå, så er vi tilbage ved at det er positivt at de nu får trykt to af deres patenter på fint papir og i laminering...
9/3 2009 17:02 ndrs 03974 Ro på nerverne kære hårdtprøvede medinvestorer. Processen er lang og bliver justeret ofte - dette er blot endnu et led. Mon ikke dette "afviste" patent, søgt af BioPorto, mangler nyhedsværdi i forhold til, you guessed it, BioPorto's eget patent. BioPorto forsøger naturligvis at opfølge deres eget hovedpatent med så mange flere af slgasen som muligt, hvoraf alle naturligvis ikke får grønt lys og har nyhedsværdi nok. De skal jo gerne presse den så langt som muligt, indenfor så mange områder som muligt.
9/3 2009 17:39 stengård 03979 fra sædvanligvis meget velinformeret kilde (det siger han selv) har jeg fået oplyst at dette IKKE berører BioP's hovedpatent - men er forsøg fra BioP's side på at udvide områderne...
Cutoff-patentet dækker niveauer over 250 - det her var et forsøg på at dække niveauer under - og svaret fra EPO er at det ikke er patenterbart - FORDI man har fået patent på de andre niveauer. Man forsøger at "kapsle" patentet ind - og det er egentlig ret smart
Cutoff-patentet dækker niveauer over 250 - det her var et forsøg på at dække niveauer under - og svaret fra EPO er at det ikke er patenterbart - FORDI man har fået patent på de andre niveauer. Man forsøger at "kapsle" patentet ind - og det er egentlig ret smart
9/3 2009 18:28 ndrs 03986 I denne "200 cut-off-patent"-sammenhæng (ng/ml), der er ganske central, vil jeg gerne henvise til seneste publikation (Clinical Journal of the American Society of Nephrology):
Først, så alle kan være med:
"Massive amounts of NGAL are released from kidney tubular cells after various injuries to the kidney."
"In a previous study, the researchers found abnormally high levels of this protein in patients who developed kidney disease and impaired kidney function. In addition, patients with higher NGAL levels had a considerably increased risk of worsening kidney function within 1 year compared with those with lower NGAL levels."
Derefter, mere teknisk, men uhyre vigtigt for BioPorto, da andre, grundet BioPorto's uomtvistelige cut-off-patent, ikke må teste indenfor samme værdi-område:
"Blood concentrations of NGAL were 515.4 ng/mL in kidney disease patients compared with 35.4 ng/mL in a group of 14 healthy control subjects matched for age, gender and blood pressure. The average urine levels of NGAL were 195.6 and 6.6 ng/mL, respectively."
"According to Buemi and colleagues, the evolution of kidney disease was significantly faster in patients with blood NGAL values above 435 ng/mL."
"Similarly, patients with urinary NGAL values above 231 ng/mL had a significantly faster progression, with an average time to progression of 13.2 months compared with 19.2 months for patients with urinary NGAL levels below this cut-off.
Blood and urine levels of NGAL predicted a higher risk of chronic kidney disease progression regardless of eGFR levels or patient age. Every increase of 10 ng/mL of urinary NGAL was associated with a 3 percent increased risk of progression, whereas an increase of 10 ng/mL of blood levels of NGAL increased this risk by 2 percent.
These findings offer a "great new tool" for preventing the progression of kidney disease, Buemi said in a statement. NGAL measurement in the blood and urine among chronic kidney disease patients could help identify those most likely to develop worsening disease who should receive aggressive treatments."
Endelig, fra neutral kilde:
"The costs of AKI are a substantial $10 billion a year, mainly from lengthy hospital stays and expensive interventions, according to Chirag Parikh, M.D., Ph.D., associate professor of medicine, Yale University Medical School. "Serum creatinine testing is inadequate. It is a non-specific marker that delays diagnosis of AKI. New biomarkers are needed to stimulate testing of new therapies and significantly decrease the mortality in AKI and costs associated with it."
Abbott og Biosite er i fuld sving med at færdiggøre deres tests, der kan måle NGAL i urin og plasma henholdsvis, og jeg kan ikke se, hvordan de skulle kunne lancere disse uden at betale BioPorto - hvilket BioPorto da også flere gange har meldt ud er tilfældet. Disse tests, der således direkte kan redde menneskeliv og spare omkostninger, kommer uomtvisteligt på markedet, og det i en meget overskuelig fremtid. Indtil nogen fortæller mig, at BioPorto's patent kan omgåes, hvilket jeg mener at have gjort en del for at undersøge, og de derved ikke får en del af en meget stor kage, vil jeg supplere i papiret fremfor at sælge.
Først, så alle kan være med:
"Massive amounts of NGAL are released from kidney tubular cells after various injuries to the kidney."
"In a previous study, the researchers found abnormally high levels of this protein in patients who developed kidney disease and impaired kidney function. In addition, patients with higher NGAL levels had a considerably increased risk of worsening kidney function within 1 year compared with those with lower NGAL levels."
Derefter, mere teknisk, men uhyre vigtigt for BioPorto, da andre, grundet BioPorto's uomtvistelige cut-off-patent, ikke må teste indenfor samme værdi-område:
"Blood concentrations of NGAL were 515.4 ng/mL in kidney disease patients compared with 35.4 ng/mL in a group of 14 healthy control subjects matched for age, gender and blood pressure. The average urine levels of NGAL were 195.6 and 6.6 ng/mL, respectively."
"According to Buemi and colleagues, the evolution of kidney disease was significantly faster in patients with blood NGAL values above 435 ng/mL."
"Similarly, patients with urinary NGAL values above 231 ng/mL had a significantly faster progression, with an average time to progression of 13.2 months compared with 19.2 months for patients with urinary NGAL levels below this cut-off.
Blood and urine levels of NGAL predicted a higher risk of chronic kidney disease progression regardless of eGFR levels or patient age. Every increase of 10 ng/mL of urinary NGAL was associated with a 3 percent increased risk of progression, whereas an increase of 10 ng/mL of blood levels of NGAL increased this risk by 2 percent.
These findings offer a "great new tool" for preventing the progression of kidney disease, Buemi said in a statement. NGAL measurement in the blood and urine among chronic kidney disease patients could help identify those most likely to develop worsening disease who should receive aggressive treatments."
Endelig, fra neutral kilde:
"The costs of AKI are a substantial $10 billion a year, mainly from lengthy hospital stays and expensive interventions, according to Chirag Parikh, M.D., Ph.D., associate professor of medicine, Yale University Medical School. "Serum creatinine testing is inadequate. It is a non-specific marker that delays diagnosis of AKI. New biomarkers are needed to stimulate testing of new therapies and significantly decrease the mortality in AKI and costs associated with it."
Abbott og Biosite er i fuld sving med at færdiggøre deres tests, der kan måle NGAL i urin og plasma henholdsvis, og jeg kan ikke se, hvordan de skulle kunne lancere disse uden at betale BioPorto - hvilket BioPorto da også flere gange har meldt ud er tilfældet. Disse tests, der således direkte kan redde menneskeliv og spare omkostninger, kommer uomtvisteligt på markedet, og det i en meget overskuelig fremtid. Indtil nogen fortæller mig, at BioPorto's patent kan omgåes, hvilket jeg mener at have gjort en del for at undersøge, og de derved ikke får en del af en meget stor kage, vil jeg supplere i papiret fremfor at sælge.
9/3 2009 18:34 ndrs 03987 Præcis - godt at se, der bliver arbejdet, alt skal prøves i "retten". Hvis BioPorto ikke kan få dette patent, betyder det blot, at deres tidligere af slagsen blokerer for dette - altså kan andre heller ikke få det.
11/3 2009 13:03 rmfw99 04241 Jeg er lidt forvirret! Er der nogen der kan hjælpe?
BIOPOR har fået patent på niveauer over 250, men afslag på niveauer under 250 med det argument, at "man" allerede har dette patent?
Er det korrekt opfattet?
Hvis ja: hvorfor søge noget, "man" allerede har? (med mindre "man" ikke er BIOPOR).
BIOPOR har fået patent på niveauer over 250, men afslag på niveauer under 250 med det argument, at "man" allerede har dette patent?
Er det korrekt opfattet?
Hvis ja: hvorfor søge noget, "man" allerede har? (med mindre "man" ikke er BIOPOR).
11/3 2009 13:52 Kim 04247 Tror du ikke det skal findes i dette fra Stengårds indlæg:
" Cutoff-patentet dækker niveauer over 250 - det her var et forsøg på at dække niveauer under - og svaret fra EPO er at det ikke er patenterbart - FORDI man har fået patent på de andre niveauer. Man forsøger at "kapsle" patentet ind - og det er egentlig ret smart "
Jeg forstår det sådan at når man har patent på "over 250 ", så dækker det også mellem 0 og 250 ......... aner ikke om det er sådan det hænger sammen, men synes det lyder meget logisk.
" Cutoff-patentet dækker niveauer over 250 - det her var et forsøg på at dække niveauer under - og svaret fra EPO er at det ikke er patenterbart - FORDI man har fået patent på de andre niveauer. Man forsøger at "kapsle" patentet ind - og det er egentlig ret smart "
Jeg forstår det sådan at når man har patent på "over 250 ", så dækker det også mellem 0 og 250 ......... aner ikke om det er sådan det hænger sammen, men synes det lyder meget logisk.
9/3 2009 15:48 stengård 03964 med de positive briller på (og det har jeg jo helst) - kan man se deres øgede markedsføringsomkostninger som et udtryk for at man regner med at have styr på likviditeten...
Selvom den slags besøg selvfølgelig ikke koster millioner - så bliver der alligevel brugt lidt penge.
Uden NGAL-aftale er der penge til start 2011 - såvidt jeg husker - men det må jo være fordi man kalkulerer med at der IKKE er behov for at spare atman udvider markedsføringen
Selvom den slags besøg selvfølgelig ikke koster millioner - så bliver der alligevel brugt lidt penge.
Uden NGAL-aftale er der penge til start 2011 - såvidt jeg husker - men det må jo være fordi man kalkulerer med at der IKKE er behov for at spare atman udvider markedsføringen
24/7 2009 07:32 Kim 015684 Faldt lige over denne artikel fra i går, hvori der fremgår nogle tal, som jeg ikke kan gennemskue. Måske en af jer andre som er mere inde i det med niveauer kan fortælle lidt om hvor BioPorto's test står i forhold til Abbott's 
http://www.medscape.com/viewarticle/706396
mvh Kim
http://www.medscape.com/viewarticle/706396
mvh Kim
24/7 2009 10:21 Kim 015694 Hmmm, prøver lige igen
http://www.medscape.com/viewarticle/706396
ellers søg på Google " abbott ngal " og begræns søgning til seneste 24 timer, for der kan den læses
Kim
http://www.medscape.com/viewarticle/706396
ellers søg på Google " abbott ngal " og begræns søgning til seneste 24 timer, for der kan den læses
Kim
24/7 2009 10:23 Kim 015696 Man er nødt til at søg på Google " abbott ngal " og begræns søgning til seneste 24 timer, for der kan den læses. Det er 9 timer siden den er lagt på nettet.
Ved ikke hvorfor linket ikke vil som det skal, for via Google kommer man direkte til artiklen
Kim
Ved ikke hvorfor linket ikke vil som det skal, for via Google kommer man direkte til artiklen
Kim
24/7 2009 13:06 stengård 015705 July 23, 2009 — A new laboratory test for urine neutrophil gelatinase–associated lipocalin (NGAL) helps predict whether patients in intensive care will develop acute kidney injury (AKI), according to the results of a study reported online July 23 in the Journal of the American Society of Nephrology.
"As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," senior author T. Alp Ikizler, MD, from Vanderbilt University Medical Center in Nashville, Tennessee, said in a news release.
A second study in the Journal of the American Society of Nephrology showed that urine NGAL may also be a useful diagnostic marker for HIV-associated nephropathy (HIVAN), which occurs primarily in black Americans and black Africans.
"NGAL was very specifically expressed in renal cysts — generating the new idea that NGAL may control the development of cysts in [HIVAN]," wrote senior author Jonathan Barasch, MD, PhD, from Columbia University in New York City. "We and Prasad Devarajan, MD, identified NGAL in the kidney 10 years ago and its translation into a clinical entity in such a short time is quite a story. Almost every paper is positive for the association of NGAL and renal dysfunction/disease."
The Vanderbilt study of intensive care unit (ICU) patients prospectively evaluated a heterogeneous population of 451 critically ill adults, of whom 64 (14%) developed AKI within 24 hours of enrollment and 86 (19%) developed AKI within 48 hours of enrollment.
Compared with those who did not develop AKI within 48 hours, those who did had higher median urine NGAL at enrollment (190 vs 57 ng/mg creatinine; P < .001). For the relationship between urine NGAL level and development of AKI within 24 hours and 48 hours, the areas under the receiver operating characteristic curves were 0.71 (95% confidence interval [CI], 0.63 – 0.78) and 0.64 (95% CI, 0.57 – 0.71), respectively.
The increase in urine NGAL in patients who later developed AKI occurred before any change in serum creatinine level, which is typically used to diagnose AKI.
After adjustment for age, serum creatinine level closest to enrollment, illness severity, sepsis, and ICU location, urine NGAL remained independently associated with the development of AKI. However, adjusted urine NGAL only marginally improved the predictive performance of the clinical model alone. Urine NGAL was an independent predictor of severe AKI during hospitalization, according to the results of a Cox proportional hazards model using time to first dialysis, adjusted for Acute Physiology and Chronic Health Evaluation II score (hazard ratio, 2.60; 95% CI, 1.55 – 4.35).
"Although a single measurement of [urine NGAL] exhibited moderate predictive utility for the development and severity of AKI in a heterogeneous ICU population, its additional contribution to conventional clinical risk predictors appears limited," the study authors write. "The role of [urine NGAL] in predicting more important measures of AKI severity, including dialysis provision or mortality, remains to be fully explored in larger cohorts."
Limitations of this study include a lack of data on incidence of death or need for dialysis, lack of data regarding renal function at baseline, and prediction models based on a single assessment of urine NGAL. In addition, creatinine measurements were made based on clinical decision-making and were not protocol-driven.
NGAL for HIVAN Diagnosis
HIVAN is defined histologically as a collapsing focal segmental glomerulosclerosis with prominent tubular damage and is characterized clinically by nephrosis and a rapid decline in renal function. The goal of the second study was to assess whether NGAL is a useful marker for noninvasive diagnosis of HIVAN.
Compared with HIV-positive and HIV-negative patients who had other forms of chronic kidney disease, expression of urinary NGAL was much higher in patients with biopsy-proven HIVAN. An HIV-transgenic mouse model of HIVAN showed an abundance of NGAL mRNA in dilated, microcystic segments of the nephron, which are characteristic features of HIVAN. In contrast, urinary NGAL was not associated with proteinuria in human or mouse models.
"These data show that marked upregulation of NGAL accompanies HIVAN and support further study of [urine NGAL] levels in large cohorts to aid in the noninvasive diagnosis of HIVAN and screen for HIVAN-related tubular damage," the study authors write.
Limitations of the human component of the study included small sample size.
"If our results are confirmed, measuring urine NGAL might help triage patients into different risk categories," Dr. Barasch concludes.
The Vanderbilt ICU study was supported by the National Heart, Lung and Blood Institute from the National Institute of Diabetes, Digestive and Kidney Diseases, and a Clinical Translational Science Award from the National Center for Research Resources. One of the study authors was partially supported by the National Kidney Foundation Research Fellowship Award and the Vanderbilt Mentored Clinical Research Scholar Program. The HIV study was supported by grants from the Emerald Foundation, the March of Dimes, and the National Institute of Diabetes, Digestive and Kidney Diseases. Columbia University and Cincinnati Children's Hospital Medical Center received licensing fees from Biosite and Abbott Diagnostics. The collection of patient specimens was supported by the National Institutes of Health and by the Clinical Research Center of the Mount Sinai School of Medicine. The study authors have disclosed no relevant financial relationships.
J Am Soc Nephrol. Published online July 23, 2009.
[CLOSE WINDOW]
Authors and Disclosures
Journalist
Laurie Barclay, MD
Laurie Barclay, MD, is a freelance writer and reviewer for Medscape.
Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
"As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," senior author T. Alp Ikizler, MD, from Vanderbilt University Medical Center in Nashville, Tennessee, said in a news release.
A second study in the Journal of the American Society of Nephrology showed that urine NGAL may also be a useful diagnostic marker for HIV-associated nephropathy (HIVAN), which occurs primarily in black Americans and black Africans.
"NGAL was very specifically expressed in renal cysts — generating the new idea that NGAL may control the development of cysts in [HIVAN]," wrote senior author Jonathan Barasch, MD, PhD, from Columbia University in New York City. "We and Prasad Devarajan, MD, identified NGAL in the kidney 10 years ago and its translation into a clinical entity in such a short time is quite a story. Almost every paper is positive for the association of NGAL and renal dysfunction/disease."
The Vanderbilt study of intensive care unit (ICU) patients prospectively evaluated a heterogeneous population of 451 critically ill adults, of whom 64 (14%) developed AKI within 24 hours of enrollment and 86 (19%) developed AKI within 48 hours of enrollment.
Compared with those who did not develop AKI within 48 hours, those who did had higher median urine NGAL at enrollment (190 vs 57 ng/mg creatinine; P < .001). For the relationship between urine NGAL level and development of AKI within 24 hours and 48 hours, the areas under the receiver operating characteristic curves were 0.71 (95% confidence interval [CI], 0.63 – 0.78) and 0.64 (95% CI, 0.57 – 0.71), respectively.
The increase in urine NGAL in patients who later developed AKI occurred before any change in serum creatinine level, which is typically used to diagnose AKI.
After adjustment for age, serum creatinine level closest to enrollment, illness severity, sepsis, and ICU location, urine NGAL remained independently associated with the development of AKI. However, adjusted urine NGAL only marginally improved the predictive performance of the clinical model alone. Urine NGAL was an independent predictor of severe AKI during hospitalization, according to the results of a Cox proportional hazards model using time to first dialysis, adjusted for Acute Physiology and Chronic Health Evaluation II score (hazard ratio, 2.60; 95% CI, 1.55 – 4.35).
"Although a single measurement of [urine NGAL] exhibited moderate predictive utility for the development and severity of AKI in a heterogeneous ICU population, its additional contribution to conventional clinical risk predictors appears limited," the study authors write. "The role of [urine NGAL] in predicting more important measures of AKI severity, including dialysis provision or mortality, remains to be fully explored in larger cohorts."
Limitations of this study include a lack of data on incidence of death or need for dialysis, lack of data regarding renal function at baseline, and prediction models based on a single assessment of urine NGAL. In addition, creatinine measurements were made based on clinical decision-making and were not protocol-driven.
NGAL for HIVAN Diagnosis
HIVAN is defined histologically as a collapsing focal segmental glomerulosclerosis with prominent tubular damage and is characterized clinically by nephrosis and a rapid decline in renal function. The goal of the second study was to assess whether NGAL is a useful marker for noninvasive diagnosis of HIVAN.
Compared with HIV-positive and HIV-negative patients who had other forms of chronic kidney disease, expression of urinary NGAL was much higher in patients with biopsy-proven HIVAN. An HIV-transgenic mouse model of HIVAN showed an abundance of NGAL mRNA in dilated, microcystic segments of the nephron, which are characteristic features of HIVAN. In contrast, urinary NGAL was not associated with proteinuria in human or mouse models.
"These data show that marked upregulation of NGAL accompanies HIVAN and support further study of [urine NGAL] levels in large cohorts to aid in the noninvasive diagnosis of HIVAN and screen for HIVAN-related tubular damage," the study authors write.
Limitations of the human component of the study included small sample size.
"If our results are confirmed, measuring urine NGAL might help triage patients into different risk categories," Dr. Barasch concludes.
The Vanderbilt ICU study was supported by the National Heart, Lung and Blood Institute from the National Institute of Diabetes, Digestive and Kidney Diseases, and a Clinical Translational Science Award from the National Center for Research Resources. One of the study authors was partially supported by the National Kidney Foundation Research Fellowship Award and the Vanderbilt Mentored Clinical Research Scholar Program. The HIV study was supported by grants from the Emerald Foundation, the March of Dimes, and the National Institute of Diabetes, Digestive and Kidney Diseases. Columbia University and Cincinnati Children's Hospital Medical Center received licensing fees from Biosite and Abbott Diagnostics. The collection of patient specimens was supported by the National Institutes of Health and by the Clinical Research Center of the Mount Sinai School of Medicine. The study authors have disclosed no relevant financial relationships.
J Am Soc Nephrol. Published online July 23, 2009.
[CLOSE WINDOW]
Authors and Disclosures
Journalist
Laurie Barclay, MD
Laurie Barclay, MD, is a freelance writer and reviewer for Medscape.
Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
24/7 2009 20:10 stengård 015741 forespurgt om der i artiklen var nævnt en cutoffværdi på 190 ng/ml, fik jeg følgende svar fra Otto Uttenthal og Christina Tønnesen - med sædvanlig hurtighed...
Først fra Otto:
Nej, de bruger ikke et cutoff på 190 ng/mL i urin, men fandt en forhøjet medianværdi på 190 ng/mg kreatinin i urin i nyreskadegruppen. Denne medianværdi er slet ikke det samme som en cutoff-værdi, og 190 ng/mg kreatinin er ikke en absolut NGAL koncentrationsværdi, men et forhold til koncentrationen af kreatinin i urin. Da der ikke gives de grundlæggende resultater for NGAL og kreatinin i urin hver for sig, kan vi ikke med sikkerhed sige noget om, hvad de absolutte NGAL koncentrationer i ng/mL kunne have været. I mange instanser ville de have en højere talmæssig værdi end værdien udtrykt pr. mg kreatinin, men man kan ikke generalisere.
Hej
De 190 ng/ml er ikke et cutoff – de omtaler det som medianen i målingerne og konkluderer i artiklen at NGAL til sammenligning er højere hos de, der udvikler nyreskade. Altså, intet nyt under solen.
Jeg har vendt sagen med udviklingen, som ikke mener disse studier bidrager med noget nyt – udover naturligvis at understrege interessen i NGAL
Med venlig hilsen / Best regards
Christina Tønnesen
hvis de efterhånden er trætte af mine spørgsmål skjuler de det godt :)
NDRS er også i gang med at tjekke gennem alverdens kanaler om lanceringen bliver udskudt til senere i 2009 - men de foreløbige svar tyder ikke på at det i givet fald er kommunikeret ud....
Vi (det vil sige mesterdetektiven NDRS og jeg) vil keep you informed on any new development :)
Først fra Otto:
Nej, de bruger ikke et cutoff på 190 ng/mL i urin, men fandt en forhøjet medianværdi på 190 ng/mg kreatinin i urin i nyreskadegruppen. Denne medianværdi er slet ikke det samme som en cutoff-værdi, og 190 ng/mg kreatinin er ikke en absolut NGAL koncentrationsværdi, men et forhold til koncentrationen af kreatinin i urin. Da der ikke gives de grundlæggende resultater for NGAL og kreatinin i urin hver for sig, kan vi ikke med sikkerhed sige noget om, hvad de absolutte NGAL koncentrationer i ng/mL kunne have været. I mange instanser ville de have en højere talmæssig værdi end værdien udtrykt pr. mg kreatinin, men man kan ikke generalisere.
Hej
De 190 ng/ml er ikke et cutoff – de omtaler det som medianen i målingerne og konkluderer i artiklen at NGAL til sammenligning er højere hos de, der udvikler nyreskade. Altså, intet nyt under solen.
Jeg har vendt sagen med udviklingen, som ikke mener disse studier bidrager med noget nyt – udover naturligvis at understrege interessen i NGAL
Med venlig hilsen / Best regards
Christina Tønnesen
hvis de efterhånden er trætte af mine spørgsmål skjuler de det godt :)
NDRS er også i gang med at tjekke gennem alverdens kanaler om lanceringen bliver udskudt til senere i 2009 - men de foreløbige svar tyder ikke på at det i givet fald er kommunikeret ud....
Vi (det vil sige mesterdetektiven NDRS og jeg) vil keep you informed on any new development :)
24/7 2009 20:44 DrueAgurken 015743 Godt at se at i arbejder drenge... jeg har stået et par timer i en blanding af brun sæbe og salmiakspritus, så jeg kunne ikke rigtig forstå hvad det gik ud på det Vanderbilt kom med der... men kan så høre at det ikke var nødvendigt med opløsningsmidler for at forstå det som noget lettere sludder.
Men noget som slår mig som jeg sidder og surfer rundt.... hold da op det må være irriterende for BioSite at have et sprit nyt produkt på hylderne, med blockbuster potentiale, og så kan de ikke markedsføre det... se hvor ensomt det står der det lille Triage kit, helt uden brugbare informationer... http://www.biosite.com/products/ngal.aspx
Men noget som slår mig som jeg sidder og surfer rundt.... hold da op det må være irriterende for BioSite at have et sprit nyt produkt på hylderne, med blockbuster potentiale, og så kan de ikke markedsføre det... se hvor ensomt det står der det lille Triage kit, helt uden brugbare informationer... http://www.biosite.com/products/ngal.aspx
25/7 2009 10:55 stengård 015753 Det er sgu ved at vre halve videnskabelige afhandlinger de her BioP tråde - hvilket selvfølgelig educerer overskueligheden. Jeg skal stærkt beklage at jeg sender endnu et bidrag tl stakken af svært tilgængelige indlæg - men jeg har endnu ikke fundet ud af at knække koden med at omskrive det til forståeligt dansk:
Så her er er endnu en række artikler om NGALs muligheder. tilsyneladende er NGAL ved at udvikle sig til en slags super-markør - der kan bruges i mange sammenhænge bl.a i forbindelse med HIV-syge... Om det får nogen praktisk betydning for BioP kan jeg dog ikke lige gennemskue - udover den selvfølgelige, at HIV-syge også skal testes - og at det åbenlyst er det rigtige segment man er i...
iøvrigt kan man finde en masse info om Abbott på følgende side:
http://www.silobreaker.com/centocor-v-abbott-edtex-5_2262479476040400896
I 1 artikel fra i dag (der er citeret nedenfor) - hvori der står yderligere om NGAL. Der er dog en enkelt sentens i den som undrer mig lidt i forhold til den ROC-test vi har set fra BioP. "The rise in NGAL was present before any change in the standard test for AKI (serum creatinine level). Without other information, however, urine NGAL was no more effective in predicting AKI than clinical risk factors" - hvilket lidt frit oversat må tolkes som at stigningen i NGAL var tilstede før ændringer i standard (Creatinine) testen - men at det ikke i sig selv medførte at man var bedre til at forudsige akut nyre skade... Men - nu er det jo taget ud af en sammenhæng - så det kan være at der er en logisk forklaring på udsagnet (det er der som regel) for eksempel at man har brugt for lave cut-off værdier eller T. Alp Ikizler har ønsket om en kombinationstest eller andet... Jeg gik så igang med at tjekke på ALp Ikizlers research og fandt følgende som jeg især synes man skal interessere sig for:
http://www.medpagetoday.com/CriticalCare/GeneralCriticalCare/15223
her bør man lytte til diskussionen med Alp Tzikler - der er ret kristisk overfor effekten af NGAL - med mindre den kombineres med andre biomarkører...
Nå - men tilbage til HIV - nichen
New Lab Test Helps Predict Kidney Damage
Main Category: Urology / Nephrology
Also Included In: HIV / AIDS; Biology / Biochemistry
Article Date: 24 Jul 2009 - 5:00 PDT
Acute kidney injury (AKI) is a frequent complication in patients in intensive care. A new laboratory test called urine neutrophil gelatinase associated lipocalin (NGAL) helps predict if patients will develop acute kidney injury, reports an upcoming study in the Journal of the American Society of Nephrology (JASN). "As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," comments T. Alp Ikizler, MD (Vanderbilt University).
Another study, also in JASN, indicates that urine NGAL may also help in diagnosing HIV-related kidney disease affecting African Americans and black Africans. "NGAL was very specifically expressed in renal cysts - generating the new idea that NGAL may control the development of cysts in HIV-associated nephropathy," says Jonathan Barasch, MD, PhD (Columbia University, New York). He adds, "We and Prasad Devarajan, MD, identified NGAL in the kidney 10 years ago and its translation into a clinical entity in such a short time is quite a story. Almost every paper is positive for the association of NGAL and renal dysfunction/disease."
In the ICU study, patients with higher urine NGAL levels were more likely to develop acute kidney injury, even after adjustment for other factors. The rise in NGAL was present before any change in the standard test for AKI (serum creatinine level). Without other information, however, urine NGAL was no more effective in predicting AKI than clinical risk factors. Ikizler notes the study was limited by a lack of information on incidence of death or the need for dialysis, and by a lack of information on the patients' initial kidney function level.
In the HIV study, levels of urine NGAL were much higher in patients with HIV-associated nephropathy (HIVAN) than in patients with other forms of kidney disease, with or without HIV. HIVAN is an important complication of HIV, occurring mainly in patients of African descent.
Studies in mice suggested that NGAL may play an important role in the development of tubular disease and microcysts, which are specific features of HIVAN. Barasch notes that the human component of their study was limited by its small size but highlights the need for larger studies that definitively measure the NGAL monomer. He adds, "If our results are confirmed, measuring urine NGAL might help triage patients into different risk categories."
yderligere info:
In Kidney Disease Caused By HIV, A Protein Excreted In Urine May Be Help In Diagnosis
Main Category: Urology / Nephrology
Also Included In: HIV / AIDS
Article Date: 25 Jul 2009 - 0:00 PDT
email to a friend printer friendly view / write opinions rate article
Ads by Google
Natural Heal for Kidney
MD-developed herbal support for Proteinuria, Glomerulonephritis
www.goutwell.com
Current Article Ratings:
Patient / Public:
Health Professional:
Article Opinions: 0 posts
New data collected at Columbia University Medical Center and by the Mount Sinai School of Medicine are helping researchers understand the extent to which a certain protein - NGAL - can play a significant role in marking chronic kidney disease resulting from HIV while at the same time distinguishing nephropathy from more common causes such as diabetes and hypertension.
It's well-known that Human Immunodeficiency Virus-associated nephropathy (HIVAN) is an important cause of kidney disease in HIV-infected patients. Antiretroviral therapy plays an important role in the treatment of HIVAN, yet despite advances in understanding HIVAN, current recommendations for treatment have largely been based on observational data and can only definitively made after a kidney biopsy.
The current study, spearheaded by Columbia University's Jonathan Barasch, M.D., Ph.D., along with Ali Gharavi M.D., Ph.D., Neal Paragas M.S., Thomas Nickolas M.D., M.S., and Vivette D'Agati M.D., together with Paul Klotman, M.D., Christina Wyatt M.D., and Susan Morgello M.D., of the Mount Sinai School of Medicine and Landino Allegri in Parma, Italy, and Prasad Devarajan in Cincinnati Childrens Hospital, represents the examination of data from human cohorts in New York and Parma, and from mouse models created by Dr. Klotman.
The team noted that NGAL, or Neutrophil Gelatinase Associated Lipocalin, a protein they previously discovered in damaged kidneys, was prominently expressed in kidney tissue and in the urine of humans and in mouse models of HIVAN. The high levels of the urine protein were out of proportion to the degree of chronic renal failure, for example that typifies patients with other types of chronic glomerular diseases of both mice and humans. Most strikingly, Paragas, Barasch, and Gharavi noticed that the rise in urinary NGAL levels was in conjunction with the development of a specific type of lesion, namely tubular cysts that typify HIVAN. The association with these cysts consequently may justify their biopsy or an aggressive treatment with antiretroviral drugs when high levels of urine NGAL are discovered.
"From what we can tell, NGAL is unexpectedly expressed in great abundance by kidney cysts allowing the clinician to potentially identify HIVAN among other types of chronic kidney diseases and hopefully to intervene to prevent a kidney from ultimately dying from what physicians refer to as ESRD, or 'end-stage renal disease,'" Dr. Barasch says.
Dr. Barasch cautions that studying a much larger human cohort would be needed in order to determine the precise relationship of NGAL to HIVAN and whether the protein is a good enough predictor of tubular cysts, but he finds the results of the study unexpected and intriguing.
The research appears in an upcoming Journal of the American Society of Nephrology and was funded in part by the Emerald Foundation, the March of Dimes, the National Institutes of Health and the Glomerular Center of Columbia University.
Not adequately diagnosing kidney problems can be life-threatening and NGAL expression which is induced in kidney disease and damage can help identify patients at risk of kidney failure even in those without HIV. Last year, Dr. Barasch and Nickolas found that approximately 65 percent of patients with NGAL protein in the urine upon presentation to the Emergency Department will require care by a nephrologist, another 32 percent will need dialysis, and 29 percent will require care in the intensive care unit, over the course of a week following the subsequent hospitalization. That study was published in the June 3, 2008, issue of the Annals of Internal Medicine.
Source:
Alex Lyda
Columbia University Medical Center
http://jasn.asnjournals.org/cgi/content/abstract/ASN.2009010065v2
og
http://www.medpagetoday.com/CriticalCare/GeneralCriticalCare/8711
Så her er er endnu en række artikler om NGALs muligheder. tilsyneladende er NGAL ved at udvikle sig til en slags super-markør - der kan bruges i mange sammenhænge bl.a i forbindelse med HIV-syge... Om det får nogen praktisk betydning for BioP kan jeg dog ikke lige gennemskue - udover den selvfølgelige, at HIV-syge også skal testes - og at det åbenlyst er det rigtige segment man er i...
iøvrigt kan man finde en masse info om Abbott på følgende side:
http://www.silobreaker.com/centocor-v-abbott-edtex-5_2262479476040400896
I 1 artikel fra i dag (der er citeret nedenfor) - hvori der står yderligere om NGAL. Der er dog en enkelt sentens i den som undrer mig lidt i forhold til den ROC-test vi har set fra BioP. "The rise in NGAL was present before any change in the standard test for AKI (serum creatinine level). Without other information, however, urine NGAL was no more effective in predicting AKI than clinical risk factors" - hvilket lidt frit oversat må tolkes som at stigningen i NGAL var tilstede før ændringer i standard (Creatinine) testen - men at det ikke i sig selv medførte at man var bedre til at forudsige akut nyre skade... Men - nu er det jo taget ud af en sammenhæng - så det kan være at der er en logisk forklaring på udsagnet (det er der som regel) for eksempel at man har brugt for lave cut-off værdier eller T. Alp Ikizler har ønsket om en kombinationstest eller andet... Jeg gik så igang med at tjekke på ALp Ikizlers research og fandt følgende som jeg især synes man skal interessere sig for:
http://www.medpagetoday.com/CriticalCare/GeneralCriticalCare/15223
her bør man lytte til diskussionen med Alp Tzikler - der er ret kristisk overfor effekten af NGAL - med mindre den kombineres med andre biomarkører...
Nå - men tilbage til HIV - nichen
New Lab Test Helps Predict Kidney Damage
Main Category: Urology / Nephrology
Also Included In: HIV / AIDS; Biology / Biochemistry
Article Date: 24 Jul 2009 - 5:00 PDT
Acute kidney injury (AKI) is a frequent complication in patients in intensive care. A new laboratory test called urine neutrophil gelatinase associated lipocalin (NGAL) helps predict if patients will develop acute kidney injury, reports an upcoming study in the Journal of the American Society of Nephrology (JASN). "As a stand-alone marker, urine NGAL performed moderately well in predicting ongoing and subsequent AKI," comments T. Alp Ikizler, MD (Vanderbilt University).
Another study, also in JASN, indicates that urine NGAL may also help in diagnosing HIV-related kidney disease affecting African Americans and black Africans. "NGAL was very specifically expressed in renal cysts - generating the new idea that NGAL may control the development of cysts in HIV-associated nephropathy," says Jonathan Barasch, MD, PhD (Columbia University, New York). He adds, "We and Prasad Devarajan, MD, identified NGAL in the kidney 10 years ago and its translation into a clinical entity in such a short time is quite a story. Almost every paper is positive for the association of NGAL and renal dysfunction/disease."
In the ICU study, patients with higher urine NGAL levels were more likely to develop acute kidney injury, even after adjustment for other factors. The rise in NGAL was present before any change in the standard test for AKI (serum creatinine level). Without other information, however, urine NGAL was no more effective in predicting AKI than clinical risk factors. Ikizler notes the study was limited by a lack of information on incidence of death or the need for dialysis, and by a lack of information on the patients' initial kidney function level.
In the HIV study, levels of urine NGAL were much higher in patients with HIV-associated nephropathy (HIVAN) than in patients with other forms of kidney disease, with or without HIV. HIVAN is an important complication of HIV, occurring mainly in patients of African descent.
Studies in mice suggested that NGAL may play an important role in the development of tubular disease and microcysts, which are specific features of HIVAN. Barasch notes that the human component of their study was limited by its small size but highlights the need for larger studies that definitively measure the NGAL monomer. He adds, "If our results are confirmed, measuring urine NGAL might help triage patients into different risk categories."
yderligere info:
In Kidney Disease Caused By HIV, A Protein Excreted In Urine May Be Help In Diagnosis
Main Category: Urology / Nephrology
Also Included In: HIV / AIDS
Article Date: 25 Jul 2009 - 0:00 PDT
email to a friend printer friendly view / write opinions rate article
Ads by Google
Natural Heal for Kidney
MD-developed herbal support for Proteinuria, Glomerulonephritis
www.goutwell.com
Current Article Ratings:
Patient / Public:
Health Professional:
Article Opinions: 0 posts
New data collected at Columbia University Medical Center and by the Mount Sinai School of Medicine are helping researchers understand the extent to which a certain protein - NGAL - can play a significant role in marking chronic kidney disease resulting from HIV while at the same time distinguishing nephropathy from more common causes such as diabetes and hypertension.
It's well-known that Human Immunodeficiency Virus-associated nephropathy (HIVAN) is an important cause of kidney disease in HIV-infected patients. Antiretroviral therapy plays an important role in the treatment of HIVAN, yet despite advances in understanding HIVAN, current recommendations for treatment have largely been based on observational data and can only definitively made after a kidney biopsy.
The current study, spearheaded by Columbia University's Jonathan Barasch, M.D., Ph.D., along with Ali Gharavi M.D., Ph.D., Neal Paragas M.S., Thomas Nickolas M.D., M.S., and Vivette D'Agati M.D., together with Paul Klotman, M.D., Christina Wyatt M.D., and Susan Morgello M.D., of the Mount Sinai School of Medicine and Landino Allegri in Parma, Italy, and Prasad Devarajan in Cincinnati Childrens Hospital, represents the examination of data from human cohorts in New York and Parma, and from mouse models created by Dr. Klotman.
The team noted that NGAL, or Neutrophil Gelatinase Associated Lipocalin, a protein they previously discovered in damaged kidneys, was prominently expressed in kidney tissue and in the urine of humans and in mouse models of HIVAN. The high levels of the urine protein were out of proportion to the degree of chronic renal failure, for example that typifies patients with other types of chronic glomerular diseases of both mice and humans. Most strikingly, Paragas, Barasch, and Gharavi noticed that the rise in urinary NGAL levels was in conjunction with the development of a specific type of lesion, namely tubular cysts that typify HIVAN. The association with these cysts consequently may justify their biopsy or an aggressive treatment with antiretroviral drugs when high levels of urine NGAL are discovered.
"From what we can tell, NGAL is unexpectedly expressed in great abundance by kidney cysts allowing the clinician to potentially identify HIVAN among other types of chronic kidney diseases and hopefully to intervene to prevent a kidney from ultimately dying from what physicians refer to as ESRD, or 'end-stage renal disease,'" Dr. Barasch says.
Dr. Barasch cautions that studying a much larger human cohort would be needed in order to determine the precise relationship of NGAL to HIVAN and whether the protein is a good enough predictor of tubular cysts, but he finds the results of the study unexpected and intriguing.
The research appears in an upcoming Journal of the American Society of Nephrology and was funded in part by the Emerald Foundation, the March of Dimes, the National Institutes of Health and the Glomerular Center of Columbia University.
Not adequately diagnosing kidney problems can be life-threatening and NGAL expression which is induced in kidney disease and damage can help identify patients at risk of kidney failure even in those without HIV. Last year, Dr. Barasch and Nickolas found that approximately 65 percent of patients with NGAL protein in the urine upon presentation to the Emergency Department will require care by a nephrologist, another 32 percent will need dialysis, and 29 percent will require care in the intensive care unit, over the course of a week following the subsequent hospitalization. That study was published in the June 3, 2008, issue of the Annals of Internal Medicine.
Source:
Alex Lyda
Columbia University Medical Center
http://jasn.asnjournals.org/cgi/content/abstract/ASN.2009010065v2
og
http://www.medpagetoday.com/CriticalCare/GeneralCriticalCare/8711
27/7 2009 16:07 jbfinvest 015817 ved ikke om i kan bruge det til noget men here it goes :
KØBENHAVN (Direkt) Abbott Labs kan glæde sig over 400 mio. nyslåede dollar i kassen efter selskabet har indgået forlig med konkurrenten Medtronic omkring en række længerevarende patentsager.
Forliget indebærer, at parterne afstår fra yderligere sagsanlæg inden for produktområdet. Abbott Labs vil indregne pengene som en engangsindtægt i tredje kvartal.
Abbott Labs producerer lægemidler og omsatte i 2008 for 29,5 mia. dollar. Selskabet har en række lægemidler inden for AIDS og HIV samt en lang række produkter inden for udstyr til sundhedssektoren.
For danske investorer er Abbott relevant, da selskabet kan blive en kommende partner for BioPorto og er tidligere samarbejdspartner med NeuroSearch.
Bertil Barkholt Fruelund +45 33 300 600
Nyhedsbureauet Direkt
KØBENHAVN (Direkt) Abbott Labs kan glæde sig over 400 mio. nyslåede dollar i kassen efter selskabet har indgået forlig med konkurrenten Medtronic omkring en række længerevarende patentsager.
Forliget indebærer, at parterne afstår fra yderligere sagsanlæg inden for produktområdet. Abbott Labs vil indregne pengene som en engangsindtægt i tredje kvartal.
Abbott Labs producerer lægemidler og omsatte i 2008 for 29,5 mia. dollar. Selskabet har en række lægemidler inden for AIDS og HIV samt en lang række produkter inden for udstyr til sundhedssektoren.
For danske investorer er Abbott relevant, da selskabet kan blive en kommende partner for BioPorto og er tidligere samarbejdspartner med NeuroSearch.
Bertil Barkholt Fruelund +45 33 300 600
Nyhedsbureauet Direkt
27/7 2009 21:30 Kim 015842 De 400 mill kan de passende videresende til BioPorto som betaling for en snarlig licensrettighed 
Jo det synes jeg godt vi kan bruge til noget, for endnu engang har Abbott måtte indgå et kompromis i forbindelse med en rettighed, og senest var det med Johnson i milliardklassen, sååååååååå deeeet
Kim
Jo det synes jeg godt vi kan bruge til noget, for endnu engang har Abbott måtte indgå et kompromis i forbindelse med en rettighed, og senest var det med Johnson i milliardklassen, sååååååååå deeeet
Kim
7/9 2009 11:50 Kim 018214 Det ser vist nu ud til at det er muligt ( ved betaling ) at få oplysninger om CCH / Abbot / Biosite's NGAL-version
http://www.informaworld.com/smpp/content~db=all~content=a794009082
http://www.informaworld.com/smpp/content~db=all~content=a794009082
7/9 2009 11:52 stengård 018215 næppe noget epokegørende nyt - det er fra juni 2008 - såvidt jeg kan se :)
7/9 2009 11:55 Kim 018216 Det havde jeg overset 
Jeg lod bare mærke til at det kun var 2 timer siden at Google havde " opdaget " linket
Jeg lod bare mærke til at det kun var 2 timer siden at Google havde " opdaget " linket 